Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 18/20 | 0.64 |
| ▸ | CCR3 | P51677 | 18/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.64 |
| ▸ | FPR2 | P25090 | 2/20 | 0.54 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412839 | 0.81 | HRH1 (0.68) | HRH1CCR3KCNH2 | |
| SCHEMBL5411633 | 0.81 | HRH1 (0.71) | HRH1CCR3KCNH2 | |
| SCHEMBL5414557 | 0.81 | HRH1 (0.85) | HRH1CCR3KCNH2 | |
| SCHEMBL4718927 | 0.80 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL18841127 | 0.80 | HRH1 (0.66) | HRH1CCR3KCNH2 | |
| SCHEMBL5407400 | 0.80 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL5409682 | 0.80 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL5411597 | 0.80 | HRH1 (0.72) | HRH1CCR3KCNH2 | |
| SCHEMBL4036160 | 0.79 | HRH1 (0.56) | HRH1CCR3KCNH2 | |
| SCHEMBL5415137 | 0.79 | HRH1 (0.71) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| EP-1404667-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004487-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR1, CCR3, CCRL2 | HRH1 25/4885CCR3 2/4885KCNH2 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.